DLL3 single domain antibodies and therapeutic compositions thereof

TW202641865APending Publication Date: 2026-10-16INHIBRX BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115121648
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-07-23
Filing Date
2019-10-09
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001081403_001
    Figure TWG2TA001081403_001
  • Figure TWG2TA001081403_002
    Figure TWG2TA001081403_002
  • Figure TWG2TA001081403_003
    Figure TWG2TA001081403_003
Patent Text Reader

Abstract

Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and / or multispecific contructs and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.
Need to check novelty before this filing date? Find Prior Art